Skip to main content
SpringerLink
Log in

Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor

  • CASE
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Imatinib is now indicated as the first line therapy for chronic myeloid leukemia (CML). Treatment of CML with imatinib is generally well tolerated and the risk of severe adverse affects is low. Many new drugs including targeted therapy are combined with antineoplastic agents safely. We here report a patient with CML who developed concurrent mesenchymal tumor while undergoing therapy with imatinib and treated with combination chemotherapy including bleomycin, etoposide, and cisplatin, as well as imatinib without severe toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004;9(3):271–81.

    Article  PubMed  CAS  Google Scholar 

  2. Latagliata R, Breccia M, Carmosino I, Sarlo C, Montefusco E, Mancini M, Natalino F, Chistolini A, De Cuia R, Russo E, Morano GS, Biondo F, Spadea A, Mandelli F, Alimena G. Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. Leuk Res 2005;29(3):287–91.

    Article  PubMed  CAS  Google Scholar 

  3. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O’Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E. International STI571 CML study group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346(9):645–52.

    Article  PubMed  CAS  Google Scholar 

  4. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O’Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99(10):3530–9.

    Article  PubMed  CAS  Google Scholar 

  5. Yasuhiko K, Miyuki A, Saburo T, Hiroyuki M, Yuko S, Yoshio H, Yusuke F. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001;97:1999–2007.

    Article  Google Scholar 

  6. Foringer JR, Verani RR, Tjia VM, Finkel KW, Samuels JA, Guntupalli JS. Acute renal failure secondary to imatinib mesylate treatment in prostatecancer. Ann Pharmacother 2005;39(12):2136–8. (Epub 2005 Nov 15).

    Article  PubMed  Google Scholar 

  7. Schmitt-Graeff A, Hochhaus A. Hematological side effects of tyrosine kinase inhibition using imatinib. Pathologe 2006;27(1):40–6.

    Article  PubMed  CAS  Google Scholar 

  8. Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S, Dupriez B, Pigneux A, Choufi B, Reman O, Stephane D, Royer B, Vigier M, Ojeda-Uribe M, Recher C, Dombret H, Huguet F, Rousselot P. Intergroupe francais des leucemies myeloides chronique; Group for research in adult acute lymphoblastic leukemia. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia 2006;20(3):400–3.

    Article  PubMed  CAS  Google Scholar 

  9. Wassmann B, Pfeifer H, Goekbuget N, Belen DW, Beck J, Stelljes M, Bornhauser M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Bruck P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer H, Ottmann OG. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph_ALL). Blood 2006;108(5):1469–77.

    Article  PubMed  CAS  Google Scholar 

  10. de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, Rea D, Cayuela JM, Vekemans MC, Reman O, Buzyn A, Pigneux A, Escoffre M, Chalandon Y, MacIntyre E, Lheritier V, Vernant JP, Thomas X, Ifrah N, Dombret H, for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007;109(4):1408–13.

    Google Scholar 

  11. Johnson FM, Krug LM, Tran HT, Shoaf S, Prieto VG, Tamboli P, Peeples B, Patel J, Glisson BS. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan inpatients with small cell lung carcinoma. Cancer 2006;106(2):366–74.

    Article  PubMed  CAS  Google Scholar 

  12. George S, Desai J, Eder JP, Manola J, Ryan DP, Appleman LJ,Demetri GD. Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumors. Eur J Can 2006;42(7):864–70.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Faculty, Department of Medical Oncology, Süleyman Demirel University, Isparta, 32040, Turkey

    Hasan Şenol Coşkun, Sema Sezgin Göksu, Mehmet Şahin & Güçhan Alanoğlu

  2. Medical Faculty, Department of Hematology, Süleyman Demirel University, Isparta, 32040, Turkey

    Hasan Şenol Coşkun, Sema Sezgin Göksu, Mehmet Şahin & Güçhan Alanoğlu

  3. Medical Faculty, Department of Immunology, Süleyman Demirel University, Isparta, 32040, Turkey

    Hasan Şenol Coşkun, Sema Sezgin Göksu, Mehmet Şahin & Güçhan Alanoğlu

Authors
  1. Hasan Şenol Coşkun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sema Sezgin Göksu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mehmet Şahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Güçhan Alanoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hasan Şenol Coşkun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coşkun, H.Ş., Göksu, S.S., Şahin, M. et al. Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor. Med Oncol 25, 110–112 (2008). https://doi.org/10.1007/s12032-007-0053-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-007-0053-5

Keywords

Search

Navigation